<< Back To Search

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Third Opinion Trial Synopsis:
This research is trying to find better ways to give a medicine called belantamab mafodotin to people with a type of cancer called multiple myeloma that has come back or hasn't responded to treatment. They want to see if changing how much and how often the medicine is given can make it work better and be safer for people.
*Third Opinion AI Generated Synopsis

Trial Summary
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?
Contacts: